US Stocks Movement | BioNTech (BNTX.US) falls over 6% after terminating Phase 2 trial of Cevumeran cancer immunotherapy

According to Zhitong Finance APP, on Friday, BioNTech (BNTX.US) opened lower, with an intraday maximum drop of over 9%. As of press time, the decline narrowed to 6.79%, trading at $103.84. In terms of news, the company announced the termination of its Phase 2 trial for the Cevumeran cancer immunotherapy. BioNTech SE announced that it has decided to terminate the Phase 2 clinical trial (BNT122-01; NCT04486378), which evaluated the investigational personalized mRNA cancer immunotherapy autogene cevumeran (BNT122/RO7198457) as an adjuvant monotherapy for the treatment of circulating tumor DNA (ctDNA) positive, surgically resected stage II (high-risk) or stage III colorectal cancer (CRC) patients. Autogene cevumeran was co-developed by BioNTech and Genentech, a member of the Roche Group. The decision to terminate this clinical trial was made after consultation with Genentech.